Abstract:Phylogenetic analyses have provided strong evidence that amino acid changes in spike (S) protein of animal and human SARS coronaviruses (SARS-CoVs) during and between two zoonotic transfers (2002/03 and 2003/04) are the result of positive selection. While several studies support that some amino acid changes between animal and human viruses are the result of inter-species adaptation, the role of neutralizing antibodies (nAbs) in driving SARS-CoV evolution, particularly during intra-species transmission, is unknown. A detailed examination of SARS-CoV infected animal and human convalescent sera could provide evidence of nAb pressure which, if found, may lead to strategies to effectively block virus evolution pathways by broadening the activity of nAbs. Here we show, by focusing on a dominant neutralization epitope, that contemporaneous- and cross-strain nAb responses against SARS-CoV spike protein exist during natural infection. In vitro immune pressure on this epitope using 2002/03 strain-specific nAb 80R recapitulated a dominant escape mutation that was present in all 2003/04 animal and human viruses. Strategies to block this nAb escape/naturally occurring evolution pathway by generating broad nAbs (BnAbs) with activity against 80R escape mutants and both 2002/03 and 2003/04 strains were explored. Structure-based amino acid changes in an activation-induced cytidine deaminase (AID) "hot spot" in a light chain CDR (complementarity determining region) alone, introduced through shuffling of naturally occurring non-immune human VL chain repertoire or by targeted mutagenesis, were successful in generating these BnAbs. These results demonstrate that nAb-mediated immune pressure is likely a driving force for positive selection during intra-species transmission of SARS-CoV. Somatic hypermutation (SHM) of a single VL CDR can markedly broaden the activity of a strain-specific nAb. The strategies investigated in this study, in particular the use of structural information in combination of chain-shuffling as well as hot-spot CDR mutagenesis, can be exploited to broaden neutralization activity, to improve anti-viral nAb therapies, and directly manipulate virus evolution.

Antibody‐dependent enhancement and neutralization against CVB4 investigated in vitro and in silico through an agent‐based model

Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera

Molecular mechanism of antibody neutralization of coxsackievirus A16

Dynamics of antibody binding and neutralization during viral infection

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

COVID-19 adaptive humoral immunity models: weakly neutralizing versus antibody-disease enhancement scenarios

Modeling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections

[Eenie, Meenie, Miney, Moe, who is responsible for the antibody-dependent enhancement of Aleutian mink disease parvovirus infection?]

Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 depends on presenting VP4 in a virus-like conformation

Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus

An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis By Cvb3 Vp1 Vaccine

Functional and in silico Characterization of Neutralizing Interactions Between Antibodies and the Foot-and-Mouth Disease Virus Immunodominant Antigenic Site

Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon

Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway

Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

Comparison of structure and immunogenicity of CVB1-VLP and inactivated CVB1 vaccine candidates

Enterovirus Antibodies: Friends and Foes

CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies

Mt10-CVB3 Vaccine Virus Protects against CVB4 Infection by Inducing Cross-Reactive, Antigen-Specific Immune Responses